Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients with Cancer
Previous Study | Return to List | Next Study

Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by University of Vermont.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Vermont
ClinicalTrials.gov Identifier:
NCT01148407
First received: June 21, 2010
Last updated: April 21, 2011
Last verified: April 2011
  Purpose

Blood samples on persons with cancer will be sampled for angiogenic, metastatic and coagulation proteins.


Condition
Cancer

Study Type: Observational
Official Title: Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

Resource links provided by NLM:


Further study details as provided by University of Vermont:

Biospecimen Retention:   Samples Without DNA

plasma, serum and platelet activated blood samples


Estimated Enrollment: 30
Study Start Date: June 2010
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with a malignancy diagnosis.

Criteria

Inclusion Criteria:

  • Patients with a diagnosis of malignancy

Exclusion Criteria:

  • Patients taking aspirin, NSAIDs, warfarin or platelet inhibitor therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01148407

Contacts
Contact: Chris E Holmes, MD, PhD 802-656-0302 ceholmes@uvm.edu

Locations
United States, Vermont
University of Vermont/Fletcher Allen Health Care Recruiting
Burlington, Vermont, United States, 05401
Contact: Barbara Kelly       bkelly@uvm.edu   
Principal Investigator: Chris E Holmes, MD PhD         
Sponsors and Collaborators
University of Vermont
Investigators
Principal Investigator: Chris E Holmes, MD PhD University of Vermont
  More Information

No publications provided

Responsible Party: Chris E. Holmes, MD, PhD, University of Vermont
ClinicalTrials.gov Identifier: NCT01148407     History of Changes
Other Study ID Numbers: VCC 0806
Study First Received: June 21, 2010
Last Updated: April 21, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Vermont:
breast cancer
platelets
metastatic cancer
malignancy

ClinicalTrials.gov processed this record on November 25, 2014